Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29325630 | 0.88 | HRH1 (0.37) | HRH1HRH2HRH3 | |
| SCHEMBL26742218 | 0.84 | HRH1 (0.39) | HRH1HRH2EHMT2HRH3MAOA | |
| SCHEMBL26752141 | 0.83 | HRH1 (0.38) | HRH1HRH2EHMT2HRH3MAOA | |
| SCHEMBL26948981 | 0.81 | HRH3 (0.35) | HRH3 | |
| SCHEMBL26742128 | 0.79 | MAOB (0.37) | HRH1HRH2EHMT2MAOAMAOB | |
| SCHEMBL29342523 | 0.76 | HRH1 (0.37) | HRH1HRH2EHMT2HRH3 | |
| SCHEMBL26742227 | 0.76 | KDM1A (0.37) | EHMT2HRH3 | |
| SCHEMBL29325624 | 0.75 | HRH1 (0.36) | HRH1HRH2HRH3 | |
| SCHEMBL27027470 | 0.75 | — | — | |
| SCHEMBL24854292 | 0.75 | OPRM1 (0.36) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HRH1 3575/4885HRH2 3194/4885EHMT2 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.